Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118896123 | 11889612 | 3 | F | 20151219 | 20160902 | 20160105 | 20160907 | EXP | IT-PFIZER INC-2016001770 | PFIZER | 10.00 | YR | F | Y | 22.00000 | KG | 20160907 | MD | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118896123 | 11889612 | 1 | PS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Intravenous (not otherwise specified) | 40 MG, QD | Y | 20987 | 40 | MG | QD | ||||||
| 118896123 | 11889612 | 2 | SS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous (not otherwise specified) | 1.32 MG, 1/WEEK | 71484 | 1.32 | MG | SOLUTION FOR INJECTION | /wk | ||||||
| 118896123 | 11889612 | 3 | SS | POSACONAZOLE | POSACONAZOLE | 1 | Oral | 160 MG, QD | Y | 0 | 160 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118896123 | 11889612 | 1 | Leukaemia |
| 118896123 | 11889612 | 2 | Chemotherapy |
| 118896123 | 11889612 | 3 | Leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118896123 | 11889612 | HO |
| 118896123 | 11889612 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118896123 | 11889612 | Off label use | |
| 118896123 | 11889612 | Seizure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |